

Stock code: 300759.SZ

Stock code: 3759.HK



2022

Annual Results Announcement



31 March, 2023



Disclaimer

The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law, and the recipients into whose possession this Document comes should inform themselves about, and observe such restrictions. By accessing this Document, you are agreeing (i) that you have read and agree to comply with the contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.


This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and nothing contained herein shall form the basis of any investment decision, contract or commitment whatsoever. This Document contains no information or material which may result in it being deemed (1) to be an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under the laws of any state of the United States. This Document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.

This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, PRC, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction’s securities laws. Upon request, the recipient will promptly return this Document and any other written information made available in the presentation, without retaining any copies.

This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation, warranty or undertaking, express or implied, is given and, so far as is permitted by law, no responsibility or liability is accepted by any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this Document or its contents. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as “will”, “expects”, “intends”, “plans to” and “anticipates” and words of similar import. These forward-looking statements reflect the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any assumptions, projections, targets, estimates, forecasts or any forward-looking statements contained in this Document. Each of the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

In furnishing this Document, the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may become apparent.



contents

Performance
Overview

1

Business
Highlights

2

Financial
Highlights

3

Growth
Strategy

4

“ **CONTENT**

01

Performance
Overview



02

Business
Highlights



03

Financial
Highlights



04

Growth
Strategy



2022 Performance Overview

18 Years

In operation

20 Locations

Operation sites in China / U.S. / U.K

>19,400

Employees (>17,400 scientists & technicians)⁽¹⁾

~30%

Total Backlog growth⁽¹⁾

Top 3

Drug discovery service provider globally⁽²⁾

All Top 20


Global pharmaceutical companies are our customers⁽¹⁾

Over 2000

Customers served in 2022


~ 800

New customers⁽³⁾



China-based customers revenue growth in 2022: **47.5%**

Overseas customers revenue growth in 2022: **35.9%**



Source: 2019 Annual Report, 2020 Annual Report, 2021 Annual Report, 2022 Annual Report


1. As of December 31, 2022;

2. By 2020 revenue, Frost & Sullivan analysis;

3. Non-IFRSs net profit for the period excludes the impact from certain expense such as Share-based compensation expenses, Convertible Bonds related gains or losses, Foreign exchange related gains or losses, Foreign exchange related gains or losses, Realized and unrealized gains or losses from equity investments


Revenue

(RMB mm)




Gross Profit

(RMB mm)



Non-IFRSs net profit⁽³⁾

(RMB mm)



China



U.S.



U.K.



Beijing HQ
Drug R&D
1.2 million ft²



Ningbo Campus I
Drug R&D
2.6 million ft²



Beijing TSP
GLP Safety Assessment
215,000 ft²



Baltimore, MD
Clinical Research
40,000 ft²



Germantown, MD
Clinical Bioanalytical
Sciences, 28,000 ft²



Hoddesdon
Discovery & Early
Development
473,000 ft²



Liverpool
CGT CDMO
103,000 ft²



Tianjin
Chemical Manufacturing
538,000 ft²



Shaoxing
Commercial Manufacturing
1,791,000 ft²



Xi'an
Chemistry
172,000 ft²



Exton, PA
DMPK, CGT
53,000 ft²



San Diego, CA
Animal Models, Tox., Ocular
and Medical Devices, 52,000 ft²



Rushden
Radiolabelled Chem. &
Metabolism, 29,000 ft²



Cramlington
Commercial API Mfg.
60,000 ft²(production area)



Nanjing
Clinical R&D
40,000 ft²



Shanghai
Chemistry
130,000 ft²



Ningbo Campus II
Biologics CDMO
350,000 ft²



Boston, MA
Biologics, CGT
24,000 ft²




Coventry, RI
Commercial API Manufacturing
63,000 ft²(production area)



Cardiff
Radiolabelled Chemistry
48,000 ft²


- According to Frost & Sullivan’s forecast, the global drug R&D and manufacturing spending from 2022 to 2027 will maintain a stable growth, of which, the pharmaceutical R&D and manufacturing spending in China is expected to grow at a CAGR of 10.7% from 2022 to 2027.
- According to Frost & Sullivan’s forecast, From 2022 to 2027, the outsourcing penetration rate of the global drug R&D and manufacturing spending will further increase from 2022 to 2027 and the market share of the Chinese drug R&D and manufacturing outsourcing services is expected to reach 25.3% in 2027.






Discovery R&D Services Trend

Global discovery CRO services market size




China's discovery R&D CRO services market size



CDMO Services Trend

Global CDMO services market size




China's CDMO services market size




Clinical Development Services Trend

Global clinical development services market size



China's clinical development services market size



“ **CONTENT**

01

Performance
Overview

02

Business
Highlights

03

Financial
Highlights

04

Growth
Strategy

2022 Business Segment Highlights

- We operate our leading fully-integrated pharmaceutical R&D services platform through four main business segments, namely, **Laboratory Services, CMC (Small Molecule CDMO) Services, Clinical Development Services and Biologics and CGT Services**, in China, the U.S. and the U.K.



Laboratory Services

Laboratory chemistry services and Bioscience services (in vitro and in vivo DMPK/ADME, in vitro biology and in vivo pharmacology, safety assessment and U.S. laboratory services).

Location: China, U.S. and U.K.

Revenue → **RMB 6,244.7 mm**

Gross Profit → **RMB 2,805.1 mm**



CMC (Small Molecule CDMO) Services

Chemistry development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services.

Location: China, U.S. and U.K.

Revenue → **RMB 2,406.7 mm**

Gross Profit → **RMB 831.7 mm**



Clinical Development Services

Overseas clinical development services (radiolabeled sciences and clinical trial services) and domestic clinical development services (clinical research services and site management services covering different service needs of clinical research).

Location: China, U.S. and U.K.

Revenue → **RMB 1,393.6 mm**

Gross Profit → **RMB 159.7 mm**



Biologics and CGT Services

Biologics discovery, development and manufacturing services (CDMO), CGT lab and Gene therapy CDMO services.

Location: China, U.S. and U.K.


Revenue → **RMB 195.1 mm**

Gross Profit → **RMB -54.1 mm**



I Laboratory Services

Revenue




Operational Highlights


- Providing customers with more flexible and comprehensive laboratory services through the collaboration of laboratory service teams in China, UK and US.
- Participating in **652** drug discovery projects and **87** IND or NDA filings, of which, **79** projects applied with multiple jurisdictions.
- **9,336** employees, increased by **2,200** in 2022, with **6,200** laboratory chemists and technicians.

Gross Profit

Margin 37.4% 40.2% 42.6% 43.4% 44.9%



Maintain world leading position in laboratory chemistry, accelerate the growth in Bioscience and strengthen the global network



2022H2, Bioscience revenue contributed to the laboratory services **more than 50%**

I Laboratory Services



Ningbo Campus III (Design Plan)



Xi'an Campus (Design Plan)

Internal and
M&A
Expansion

■ Infrastructure

- Remaining **42,000m²** laboratory space was in the process of internal installation.
- Commenced the construction of **140,000m²** safety assessment and *in vivo* bioscience facility in Phase I of Ningbo Campus III and expected to be operational in H2 2023.
- Expanding the laboratory spaces over **70,000** square meters in Beijing and has commenced operation gradually from 2022.
- Begun on the **105,000m²** laboratory at the Xi'an Campus, which is expected to be commissioned in 2024


Ningbo Campus I



Qingdao



New Laboratories in Beijing




II CMC (Small Molecule CDMO)

Maintain core competent on early-stage project, expand to late and commercial stage manufacturing services with our service networks in China, US and UK

Operational Highlights





- With the seamless integration of the Company's fully-integrated R&D service platform, over **80%** of CMC (Small molecule CDMO) revenue came from the drug discovery services customers.
- ~80%** of CMC (Small molecule CDMO) revenue was generated from preclinical to Phase II clinical trial stages.
- 3,978** employees, increased by **1,357** from December 31, 2021.

Revenue



Gross Profit

Margin: 21.7% 27.7% 32.6% 34.8% 34.6%



II CMC (Small Molecule CDMO)



Shaoxing, China

Internal and
M&A
Expansion

■ Infrastructure

- With the strategy to extend CMC (small molecule CDMO) service downstream to late-stage clinical and commercial manufacturing services, company have almost successfully completed the construction of Shaoxing Phase I facility with an area of **81,000m²** and reactor volume of **600m³** and has commenced operation gradually in 2022.


■ M&A expansion

- Acquired Aesica Pharmaceuticals Limited (now “Pharmaron Manufacturing Services (UK) Ltd”) in **Cramlington**, U.K. and API manufacturing facility in **Coventry**, Rhode Island, U.S. These two facilities can provide cGMP API manufacturing services from pilot to commercial scale and have been inspected and approved by a number of regulatory agencies including the FDA.




CDMO sites in UK and US

Global Small Molecule CDMO Capacity Layout



III Clinical Development Services

Revenue






Operational Highlights

Continue to develop specialty clinical services overseas, establishing fully-integrated clinical development services platform in China

- Continued to strengthen our fully integrated clinical development services platform in China under the “Pharmaron Clinical” brand, China-based clinical development services achieved a revenue growth of **65.5%** in 2022.
- With the rapid increase in revenue as a result of increased market recognition, the overall gross margin of clinical development services increased by **1.2%** in 2022 as a results of economy of scale and increased in operating efficiency.
- In 2022, Pharmaron Clinical had more than **800** ongoing projects, Clinical research site management service, there were more than **1,100** ongoing projects.
- 3,602** employees, increased by **245** from December 31, 2021.

Gross Profit



III Clinical Development Services




Internal and
M&A
Expansion

Global Offices	Global Employees
20	3,600+
SMO Cities covered in China	Cooperation hospitals and clinical trial centers
120+	~600




- Integrated platform of “radioisotope compound synthesis – clinical – analysis”, established by effectively combining the advantages in radiolabel technology and clinical basis in the UK and US, has been widely recognized by customers.
- In August 2022, Pharmaron Clinical passed the physical inspection by the expert group from Center for Food and Drug Inspection of NMPA (CFDI) for the various clinical trial projects performed




IV Biologics and CGT Services

Revenue





Gross Profit



Operational Highlights

Establish world-leading end-to-end CGT services platform, continue to build the services capabilities in Biologics development and manufacturing

- Currently, the Company has more than **50** CGT programs at various stages for analytical release testing, including **19** potency assays for clinical studies and **2** potency assays for commercial manufacture
- For the safety assessment services, over **40** non-GLP and GLP toxicology studies for CGT products either have been completed or are in progress at the Company.
- Delivered over **100** runs of productions of various AAV projects including manufacturing of full scale GMP products.
- The Company's gene therapy CDMO service began to take third-party customer orders by the end of 2021 and currently has around **29** gene therapy CDMO projects across different services offerings and R&D stages.
- 490** employees, increased by **149** from December 31, 2021.



IV Biologics and CGT Services




Biologics CDMO in Ningbo



Gene Therapy CDMO in Liverpool



Internal and
M&A
Expansion



CGT Laboratory Services in the US

■ Infrastructure

- **Biologics CDMO in China:** Large molecule GMP production service projects (Nearly **70,000m²**) is expected to undertake in **Q3 2023**.
- **Overseas CGT CDMO :** End-to-End CGT Service Platform. For the plasmid development and manufacturing, the Company has proprietary cell line and plasmid technology and optimized production processes for GMP plasmid manufacturing up to 500L scale. For CDMO of vector, the Company has suspension based production platform with SUBs ranging from 50L to 500L.

■ Reorganization & Financing


Pharmaron Biologics & CGT: To accelerate the establishment of the biologics and CGT services, an internal reorganization was carried out to group the biologics discovery and CDMO capabilities in China, ABL in UK and Absorption System in the US under the name of Pharmaorn Biologics & CGT and followed by an external financing of **950 million RMB** to support the future growth. After the completion of the financing, the company's shareholding on Pharmaron Ningbo Biologics will be reduced to **88.89%**.




End-to-End Cell & Gene Therapy Services Overview

Discovery (Candidate Screening)	Proof-of-Concept (Non-GLP)	Preclinical - IND Enabling (GLP/Non-GLP)	Clinical Development (IND - BLA/MAA)
In Vivo Screening (In life: rodents)	Efficacy, PK/PD Studies (In life: rodents)	IND Enabling GLP Toxicology (Rodents and larger species)	Process Compatibility and Stability for Clinical Trial
Discovery Bioanalysis (Expression/Activity)	Preclinical PK/PD Bioanalysis	GLP Bioanalysis (Biodistribution, Shedding)	Clinical PK Sample Bioanalysis Clinical Shedding
Immunogenicity Humoral (ADA)	Immunogenicity Humoral (ADA, NAb)	Immunogenicity Cellular (ELISpot)	Clinical Sample Bioanalysis Immunogenicity, Biomarkers
In Vitro Screening (Cell Lines)	R&D/Working Cell Bank	GMP Cell Bank Production	Process Characterization and Validation
Analytical R&D Testing	Potency Assay R&D Development	Potency Assay Development & Qualification/Other analytical	Potency Assay GMP Qualification
Candidate Cloning	R&D Manufacturing (Plasmid, DS)	DS & DP Process/Formulation Development & Manufacturing	Clinical Batch Manufacturing
For Gene Therapy Products			

Employee Total and Distribution



NO. of Employees continues to grow



Diverse Welfare Scheme

- During the reporting period, we launched 3 batches of equity incentive programs—one restricted equity incentive program motivating 554 employees in total
- The social insurance coverage for full-time employees reached 100%.



Biocatalysis

We have produced about 3,000 catalytic enzymes, including over 600 genetically modified mutant enzymes. As we are more experienced and mature, we see more efficient development, with over 700 new enzymes developed in 2022 alone. Leveraging our enzyme screening and directed-evolution platforms, we also provided services for our clients to identify high selective enzymes for chiral compound synthesis and production.



Flow chemistry (continuous production technology)

In 2022, the Company introduced new technologies and means such as continuous photochemistry and Online-Mass online monitoring, continuous technology was applied to the scaling up and production of more than 100 PDM projects. In terms of capacity building, the Company built the whole process continuous technology platform of non-GMP continuous reaction, continuous quenching, continuous separation and continuous online monitoring of PAT in Tianjin plant.



High-throughput experimentation (HTE) platform for reaction condition screening

More than 350,000 conditions for over 6,400 reactions in 2022



DNA-encoded chemical library technology platform

Over 15 billion new small molecule drug-like compounds with innovative and unique structures in our collections. Many DNA-encoded chemical probes and DNA-encoded compound libraries were effectively synthesized. Submitted 19 patent applications to the Chinese Patent Office, and one research paper has also been accepted by a peer reviewed journal.



Chemical proteomics platform

Strength of chemical proteomics platforms by screening covalent binder libraries and established the high-throughput workflow to identify the new targets.

CMC

(Small Molecule CDMO)

Laboratory Chemistry

Biosciences



3D spheroid and organoid models

Successfully established nearly 200 cases of human-derived 3D-spheroid models for drug screening. For tumor organoids, the Company has successfully developed robust methodologies for the construction of various tumor organoids including colon cancer, gastric cancer, lung cancer, esophageal cancer, etc., while a strict quality control process has been developed and implemented to ensure the quality of the organoid.



Imaging technology platform

Established in-vitro cell based imaging and in-vivo animal-based imaging Cellular imaging-based high-content technologies: completed the first run of high-throughput campaign of compound library screening project aimed to evaluate the protein translocation driven by treatment of test articles in engineered cell lines genetically expressing fluorescently tagged proteins. The in vivo imaging system (IVIS): we have established 270 luciferase-expressed tumor cell lines and 112 orthotopic or metastatic tumor models, which cover 30 different cancer types and have been widely utilized in tumor pharmacodynamic studies and related fields.



Gene editing technology platform

Introduced a number of advanced gene editing technologies, which significantly improved the experimental success rate and shortened the turnaround time, covering expression regulation of targeted proteins, protein overexpression and suppression with or without inducers. We provided services in gene knockout, gene knock-in and targeted mutation to our clients and helped complete early target validation and compound efficacy screening.

ESG Governance

- Built a three-tiered ESG governance framework with “governance, management, and implementation” level
- Issued and implemented the ESG Management Measures and the ESG Information Management Handbook
- Developed the 2021-2025 environmental targets
- Issue the first standalone ESG Report

Responsible Operations

- High-quality products
- Innovative technologies
- Quality Services
- Stable and sustainable supply chain

Empowering Talent Development

- Equality and diversity
- Talent attraction and retention
- Employee health and safety

Engaging in Charity and Public Welfare


- Public Welfare Platform
- Public Welfare Actions

Ethics and Compliance

- Business integrity, improve regulatory compliance, 0 legal actions due to corruption or fraud.
- Information Security
 - Ethics of Clinical Trials
- Animal Welfare
- Marketing Compliance


Environmentally Sustainable and Low-Carbon Operations

- Responding to Climate Change
- Sustainable Environmental Goals
- Environmental Management
- Pollution Prevention and Control
- Resource Protection



Green and Low-Carbon Operations

2021-2025 Environmental Targets



Maintaining **100%** compliance in waste disposal

2022 MSCI ESG:BBB



ISS Governance: Continued to maintain a high-level ISS Governance rating among the industry.



Achieved a "B" scoring for CPD Climate Change Questionnaire.



- Signed the SBTi Commitment Letter.
- The Company has been ISO14001-certified.
- Joined the ACS GCI2 Pharmaceutical Roundtable.
- Received a Gold certification from the My Green Lab.

In the 12th China Securities Golden Bauhinia Awards, the Company won the award of "Best ESG Practice Listed Company"

Awards and Recognitions

- Included in **HSCI, HSHCI, MSCI China Health Care Index, CHINEXT Composite, SZSE Component Index**



Influential Enterprise of the Year awarded on CCV Award Ceremony



Top 50 Valuable Listed Companies on GEM



Best ESG Practice Listed Company



Eighth of the “Top 25 Pharmaceutical Companies”



Top 20 Chinese Pharmaceutical CRO Enterprises in 2022



Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprises



Overseas Market Exploration Achievement Award

“ **CONTENT**

01

Performance
Overview

02

Business
Highlights

03

Financial
Highlights

04


Growth
Strategy



2022 Financial Performance

RMB mm


Revenue




Gross and Profit

RMB mm

Gross Profit and Margin



Net Profit⁽¹⁾ and Margin



Non-IFRSs net profit attributable to owners of the company⁽²⁾



RMB mm

Net Cash Flows Generated from Operating Activities



Source: 2022 Annual Report.


Note: Data are rounded to the nearest million.

1. Net profit attributable to owners of the parent.

2. Non-IFRSs net profit for the period excludes the impact from certain expense such as Share-based compensation expenses, Convertible Bonds related gains or losses, Foreign exchange related gains or losses, Foreign exchange related gains or losses, Realized and unrealized gains or losses from equity investments

2022 Non-IFRS adjusted net profit attributable to owners of the parent

RMB mm	2021	2022
Profit attributable to owners of the parent	1,661.0	1,374.6
Add:		
Share-based compensation expenses	56.8	157.2
Convertible Bonds related (gains)/losses	(12.9)	142.0
Foreign exchange related (gains)/losses	(23.4)	77.7
Realized and unrealized (gains)/losses from equity investments	(219.5)	82.8
Non-IFRS adjusted net profit attributable to owners of the parent	1,462.0	1,834.3







Solid Growth on Revenue and Profitability of the Established Business Segments

Both revenue and non-IFRSs net profit of the established business segments excluding impact from **Biologics and CGT Services** and the **addition of overseas small molecule manufacturing capacities** achieved solid growth in the first 9 months of 2022.

- **Biologics and CGT Services** - Since 2021, we began to build our Biologics and CGT Services through internal buildup and external acquisitions for the medium and long-term growth of the company. As these new business are still in the integration and investment stage, there are certain negative impact on the profitability in 2022.
- **Addition of overseas small molecule manufacturing capacities** - Since 2022, with the strategy of establishing a global service network for the small molecule CDMO services, we have acquired manufacturing sites in UK and US in January and July 2022, respectively. As we are in the process of integrating these manufacturing capacities into our services platform, there are certain negative impact on the profitability in 2022.




Note:
Adjusted numbers exclude the impact of Biologics and CGT Services in 2021&2022, and Overseas Capacity Layout of CMC (small molecule CDMO) Services in 2022.


2022 Expenses

- **Administrative expenses as % of Total Revenue:** During the reporting period, the Company completed several overseas acquisitions. With the relatively low revenue in the integration stage, the administrative expenses as % of total revenue increased.


Selling and distribution expenses as % of Total Revenue




Administrative expenses as % of Total Revenue ⁽¹⁾



Research and Development Cost as % of Total Revenue



Net finance costs as % of Total Revenue ⁽²⁾




Source: 2019 Annual Report ,2020 Annual Report , 2021 Annual Report and 2022 Annual Report .


Note:1.Excluding share-based compensation expenses recognized in administrative expenses.

2. Net finance costs including interest expenses on bank borrowings and lease liabilities, interest income and bank wealth management products related gains or losses


Trade Receivables and Contract Assets Turnover⁽¹⁾




Trade Payables Turnover⁽²⁾



Inventories Turnover⁽²⁾



Contract Costs Turnover⁽²⁾



Source: 2019 Annual Report, 2020 Annual Report, 2021 Annual Report, and 2022 Annual Report.


1. Calculated based on average of the opening and closing balances of sum of trade receivables (before adjustment of allowance for impairment) and contract assets (before adjustment of allowance for impairment) for the relevant year/period, divided by the corresponding revenue for the year/period, and then multiplied by 360 days for a year.

2. Calculated based on average of the opening and closing balances for the relevant year/period, divided by the corresponding cost of sales for the year/period, and then multiplied by 360 days for a year.




2022 Capital Expenditure, Bank-related Assets , Bank Facilities and Loans

Capital Expenditure



Bank-related Assets, Bank Facilities and Loans ^{note}



Notes:
Bank-related Assets including cash and cash equivalents, bank wealth management products , etc. Loans including bank loans and convertible bonds, convertible bonds are listed at par value * exchange rate as at Dec 31, 2021&Dec 31 2022

“ **CONTENT**

01

Performance
Overview

02

Business
Highlights

03

Financial
Highlights

04

Growth
Strategy



- Continue to build and improve our “end-to-end, fully integrated and global” pharmaceutical R&D service platform

Continue to strengthen the fully integrated clinical development services platform

Strengthen the leading position in the small molecule R&D service area

Continue accelerating the build-up of biologics and CGT services platform

Continue to strengthen our talent pool to support our long-term and sustainable growth

Further enhance management capabilities

Continue to expand domestic and overseas market shares



Thank You!